I’m 36 minutes into this one and plenty of horrifying and jaw dropping moments so far.
And not only horror stories about the vaccines either. At 32 minutes in we find out that when people who are behind with the payments on their homes for a few months sign up to a sort of “pay later” scheme", it’s the CDC that becomes the new owner of the lease!
Apparently the CDC is now the largest leaseholder in the US.
A disconcerting video…
So it’s going to get worse if you resist. The questions are obviously when and by how much?
We desperately need an update on this question of side effects and deaths, as this was now a month and a half ago, and since then many millions have had a dose, and some the second one in the US. I don’t doubt that there are many side effects not being reported, and possibly serious ones or deaths attributed to other causes, but just half a dozen blood clots caused by the AZ vax have caused huge ructions, so what about the Pfizer-specific problems? Something odd going on, compounded by total control of media, vested interests, and political expediency. If the mRNA vax are not causing the expected side effects after all, then these anti sources will not be in a hurry to admit it, and will assume effects are being hidden.
The manipulation of data and reality is getting beyond control - with the 'third wave" that may not even exist, and the apparent herd immunity in the UK which no-one has even suggested. Why else have cases dropped consistently since January, with a slight flattening off recently?
Thanks for the post. This contains excellent explanations from Sheri Tenpenny regarding the specific risks and mechanisms the mRNA vaccines are expected to cause harm. She and perhaps Judy Mikowicz have been making the most stark predictions (and over here, Dr Vernon Coleman). So according to this line of thought, the concern is not just a risk that has been taken - they think it’s likely to cause a lot of deaths and illnesses as people gradually encounter new variants. Tenpenny outlines three distinct mechanisms of harm (see post below).
Rich you say: “Apparently the CDC is now the largest leaseholder in the US.”
Strangely the spectre of party politics is never far away. I think this refers to a measure taken to protect renters from being thrown out when they fall behind with their payments. The idea was (supposed to be) that this would prevent the spread of the virus from accelerating from the resulting overcrowding as evicted people went to friends, hostels or the streets. I might have this wrong but the idea this makes the CDC ‘the leaseholder’ or landlord seems to be a right wing gripe that landlords can’t evict tenants.
[Edit: I seemed to somehow lose an edit I thought I’d made]
I couldn’t find anything to suggest anything more devious.or that CDC protection might be vaccination-dependent as Reinette Senum suggested.
Though the plan to ‘save’ tenants seems to have been half-hearted as it left wiggle room for landlords to evict tenants for reasons other than rent, one that they are apparently taking advantage of.
Towards the end of the video Reinette Senum kind of goes off on one, while Dr Tenpenny has to just sit there. That said they both firmly stated their belief that the vaccine would kill people and it was likely part of a depopulation policy. Senum makes reference to China, where, invasive surveillance is already advanced. This bolsters the frequently expressed Republican view of lockdowns, the vaccination drive and control measures and even the Great Reset as a “Commie plot”, as if China and communism represent the worst nightmare.
This is Dr Tenpenny’s explanation I referred to of how the mRNA can cause damage:
"…genetics specifically for spike, creating non-neutralizing antibodies, instead of gobbling up (the threat) creates ADE. Allows that piece of mRNA to start replicating on its own creating little virus spikes for antibodies. Bill Gates - humans can become their own antibody manufacturing machines.
That spike protein can injure in 3 ways.
(i) Antibodies (look like Y in literature). The 2 arms called FAB fragments, the stem is called FAC.
FAB grab hold of the virus, and neutralizes it. The mRNA grabs hold of it but loosely binds it, but when FAC hooks on to the macrophage that’s supposed to kill it, and it’s taken inside, the mRNA gets released, and that’s where it starts to replicate over and over again. There’s no OFF button. This is called the Trojan Horse mechanism. Because it allows the mRNA piece to get into your cells and even other parts of your DNA.
(ii) When you create this antibody, this Non-neutralising antibody, that stem can actually go into your lungs and attach to the lung tissue and start developing what they call a diffuse aveolar damage. Which is diffuse injury to the cells inside your lungs where you breathe. It starts to break them down and destroy them. What these antibodies do, they cause various degrees of pus and bleeding and damage to your lungs.
(iii) The third and even more sinister thing is that spike protein AB can attack your macrophages.
There are 2 types of macrophages. Type 1 are a type of White Blood Cell that gobble up bacteria/viruses that aren’t supposed to be there. Your TH1 pathway, your hyper-vigilant WBC…All the antibodies you create during the day (eating, brushing teeth, going to the bathroom, having sex, cutting your fingers) these WBC gobble them up and make them go away. When you get eg pneumonia, the Type 1 macrophages are pro-inflammatory, they show up with the infection and start creating cytokines and various things to try to kill off the infection - very highly inflammatory. Which is what you want. The Type 2 macrophages are anti-inflammatory. As you start to recover, they tell the other guys to shut up, we’re here to clean up the mess, clean up the tissue, the dead macrophages. So the Type 1 and Type 2 macrophages work in concert Type 1 kill off the infection, Type 2 heal it. When you’ve got this antibody to the spike protein - the full purpose of these vaccines - that antibody kills your Type 2 macrophages; it attaches to them and inactivates them. So in the experimental animals that actually died - when they sacrificed them, they found the lungs were filled up with these Type 1, pro-inflammatory, highly cytokine types of macrophages and zero Type 2 macrophages. When they sacrificed the animals that had not been vaccinated but that had been sick they found that within 2 days of getting sick the Type 2 macrophages had come in and started cleaning up the mess and started healing it. As long as they didn’t have the presence of the spike antibody. When the spike antibodies were present they killed the macrophages and didn’t allow them to do their job.
That’s 3 of maybe 7. The antibody to the spike protein is going to destroy lungs, it’s going to shut off M2 anti-inflammatory macrophages and the spike protein antibody is going to loosely bind that mRNA and drag it into your cell and make it replicate but will repeat with no OFF button.
If you look back at all the studies going back to 2002 about how they tried to develop a coronavirus vaccine - you get this antibody and then garden-variety coronavirus shows up and activates this whole process - it’s the re-exposure that leads to Antibody-Dependent Enhancement, this accelerated auto-immune disease. There are 36 CV’s 7 known to infect humans. We’re going to get those antibodies, these non-binding antibodies. A CV is gonna show up and start killing people. Not right away though some are going to die from anaphylactic shock and some from cardiovascular disease.
The doctor that died…ITP which is a blood disorder, this auto-immune disease, probably the spike protein antibody, starts attacking the red blood cells breaking it down and you die from that. And so some people are going to die from the vaccine directly. But a large number of people are going to get horribly sick and get all kinds of auto-immune diseases. 42 days to maybe a year out, what are they gonna do these stupid doctors saying good for you on getting that vaccine, we need to get you an extra dose of that vaccine, because the stupid physicians aren’t taking the time to learn anything about it. If I can learn it in my living room so can they.
Reinette Senum: Moderna’s ingredients have not even been released is that correct?
RS: Our governor in the state of California Newsome is possibly going to be bringing in military and pushing everybody to be vaxxed and theyre certainly threatening the hospitals right now, saying they’re not vaccinating quickly enough, threatening funding of different sorts. We’re also getting reports of people being given the vaccine who are on their deathbed. …what went wrong with our system?
ST: Well it didn’t start with Covid, I’ve been saying this for decades. (Explains, growing since the 30s, related to child vaxn programme, more info here…when Rockfeller tookover the med system)
Drs are supposed to be experts in anatomy, biochemistry and physiology. But we decided what was impt was matching symptoms with a pill, and pharmacology and surgery was what it was about to be a Dr.
RS: Talking about vaccination before student loans.
Newsome said there would be a moratorium on rents, if you could pay maybe a quarter that would be great, you pay it later. But do you know when a person applies, who the lease holder is? The CDC.
SP: No!
RS: The CDC is now the largest leaseholder in America."
…
Hi Dimac. This article might interest you. It’s a rare, honest appraisal of the development of the blood clots story in what has become a bit of an AZ vaccine saga.
By Kai Kupferschmidt, Gretchen Vogel
In the tumultuous rollout of AstraZeneca’s COVID-19 vaccine, all eyes were on the United States this week, where the company had a highly public communication breakdown over the vaccine’s efficacy with an expert panel overseeing a large study in the Americas. But on the other side of the Atlantic, the vaccine faces new concerns about safety as an explanation gains ground for the unusual strokes and clotting disorders recorded in at least 30 recipients.
Many European countries suspended use of AstraZeneca’s vaccine earlier this month following initial reports of the symptoms, which have led to at least 15 deaths. Most resumed vaccinations after the European Medicines Agency (EMA) recommended doing so on 18 March, saying the benefits of the vaccine outweigh any risks. EMA is continuing to investigate the matter and will convene a wideranging committee of experts on 29 March.
Now, a group of researchers led by German clotting specialist Andreas Greinacher of the University of Greifswald says the highly unusual combination of symptoms—widespread blood clots and a low platelet count, sometimes with bleeding—resembles a rare side effect of the blood thinner heparin, called heparin-induced thrombocytopenia (HIT).
The scientists, who first described their findings during a 19 March press conference, recommend a way to test for and treat the disorder and say this can help ease worries about the vaccine. “We know what to do: how to diagnose it, and how to treat it,” says Greinacher, who calls the syndrome vaccine-induced prothrombotic immune thrombocytopenia, or VIPIT. Greinacher says he has submitted a manuscript to the preprint server Research Square.
Even if Greinacher’s mechanism isn’t the whole story, multiple researchers told Science they were convinced that the vaccine was causing the rare set of symptoms. If that turns out to be true, it could have major consequences for the vaccine, which is one of the cornerstones of the World Health Organization’s push to immunize the world. AstraZeneca is working with partners around the globe to make and distribute billions of doses in low- and middle-income countries, which might have a harder time identifying and treating rare side effects.
Europe is relying heavily on the vaccine as well; the European Union bought 400 million doses. The company’s failure to deliver on time has delayed vaccine rollouts on the continent, but now, dented confidence is exacerbating the delays. And even if the risk is very low, it may make sense to use the vaccine only in those who also stand to gain the most from it: elderly people at high risk of dying from COVID-19. Several European countries have started to do this. The situation has scientists walking a tightrope: They want to make the medical profession aware of their concerns without sowing panic.
But Greinacher’s hypothesis is being taken seriously. Two German medical societies put out press releases lauding him for solving the issue. In the Netherlands, the Dutch Internal Medicine Society urged internists to be aware of the symptoms and the recommended course of action. The United Kingdom has officially reported only 5 cases—despite administering 11 million doses of the AstraZeneca vaccine—but the British Society of Haematology has urged its members to be aware of “an important and emerging area of haemostasis and thrombosis practice” and to report any possible cases. The Australian Technical Advisory Group on Immunisation has recommended against giving any COVID-19 vaccine to people with a history of HIT.
It is not yet clear how the vaccine could trigger VIPIT, and not everyone thinks the case is closed. “It’s intriguing, but I am not entirely convinced,” says Robert Brodsky, a hematologist at Johns Hopkins University. AstraZeneca, meanwhile, has not directly responded to the reports of the rare constellation of symptoms except to say that they did not appear in any of the company’s clinical trials.
“People are absolutely working like crazy behind the scenes to provide more clarity,” says Saskia Middeldorp, a vascular internist at Radboud University Medical Center in the Netherlands, who disagreed with the temporary halt of the vaccine because she says the benefits clearly outweigh the risks.
The VIPIT story began on 27 February, when Sabine Eichinger, a hematologist at Medical University Vienna, was confronted with an unusual patient. A 49-year old nurse had sought help at a local hospital the day before, suffering from nausea and stomach discomfort, and was transferred to Eichinger’s hospital. She had a low platelet count and computed tomography scans found thromboses—blood clots—in the veins in her abdomen and later in arteries as well. “There was little we could do at this stage,” says Eichinger. The patient died the next day.
The combination of low platelet count, or thrombocytopenia, and clots kept Eichinger thinking, however. “It’s very striking,” she says. Platelets, also known as thrombocytes, help to form blood clots, so low levels usually lead to bleeding, not clotting. “You would think that low platelets and thromboses are opposites really.” One condition where they occur together is called disseminated intravascular coagulation, when severe infection, injury, or cancer trigger clotting so widespread it uses up all the platelets, “but she had none of these things,” Eichinger says.
The unusual combination also appears in HIT, which can occur in patients given heparin as a drug. Heparin binds to a protein called platelet factor 4 (PF4), forming a complex. For reasons that aren’t understood, some people produce antibodies against the complex, setting off an out-of-control clotting reaction. Eichinger’s patient had not received heparin, but she had gotten a shot of the AstraZeneca vaccine 5 days before her symptoms began. “I thought maybe this is some kind of immune reaction," Eichinger says.
She reached out to Greinacher, who had studied HIT for decades. “Then things started happening thick and fast,” she says, as multiple countries responded to reports of clotting by suspending use of the AstraZeneca vaccine.
Greinacher says he contacted other colleagues who had studied HIT in Canada and Germany and asked the Paul Ehrlich Institute (PEI), which oversees vaccine safety in Germany, if they had seen any cases. They had. PEI recommended that Germany pause use of the vaccine as well and asked Greinacher to help investigate. He soon received blood samples from eight additional patients. All had both low platelets and unusual clotting, he says. In four samples, the researchers also found evidence for antibodies against PF4, a hallmark of HIT. He and his colleagues are now checking whether other vaccine recipients and former COVID-19 patients have similar antibodies.
Brodsky says it isn’t clear whether VIPIT explains all of the cases. He agrees that the PF4 antibodies and the clotting seen in patients resemble HIT, but the link has not been proven, he says: “I’m convinced that these patients have platelet factor 4 antibodies, at least four of them. But I’m not convinced that those … antibodies are explaining the thrombocytopenia or the clotting.”
Greinacher agrees on the need for more data. But he says it’s crucial to alert doctors to the potential complication. When recognized in time, HIT can be treated with immunoglobulins—nonspecific antibodies from blood donors—that help put the brakes on platelet activation. Non-heparin blood thinners can help dissolve the clots. VIPIT should be treated in a similar way, he says. In at least one case, Greinacher says, a doctor sought the group’s advice and the patient recovered. The German Society for the Study of Thrombosis and Hemostasis, of which Greinacher is a member, has issued a set of recommendations for diagnosing and treating VIPIT. Greinacher says he has also been in touch with safety representatives at AstraZeneca.
Nigel Key, a hematologist at the University of North Carolina at Chapel Hill, agrees on the need to alert doctors. “Maybe it is too much to expect at this point that there would be a very detailed molecular mechanism,” he says, but the advice to physicians who may encounter patients is crucial.
Brodsky and Key say the cases are striking enough that they probably represent a real side effect. “I think the vaccine is mostly safe. I think the benefits probably outweigh the risk for a general population,” Brodsky says. “But these cases raise concern that this vaccine is potentially life-threatening in a small subset of patients.”
Scientists are now scrambling to understand how big that subset is and who’s in it. So far, most cases have been observed in women under 65. But that could be because of the vaccinated population: Many countries initially used AstraZeneca only in people under 65 because early clinical trials included few older recipients. That meant the vaccine was used in priority groups such as health care workers and teachers, a majority of whom are women. In Norway, for example, 78% of the AstraZeneca doses went to women, says Sara Viksmoen Watle, chief physician at the Norway Institute of Public Health. The United Kingdom, however, used the vaccine first in older people, which may explain why fewer unusual clotting events have been spotted there.
Data from Norway—whose extensive health registries make this type of research easier—suggests previous COVID-19 infection does not predispose vaccinees to a severe reaction, Watle says. Alerting clinicians will help ensure that fewer cases are missed for analysis, Key says. A global database of cases may be helpful too.
Many countries are, for now, accept the risk that the AstraZeneca may carry, but several have restricted its use to people who are at the highest risk of dying from COVID-19: those aged 55 or older in France, 65 or older in Sweden and Finland, and 70 or older in Iceland. That approach makes sense, says Sandra Ciesek, a virologist at Goethe University Frankfurt. “The argument I keep hearing is that the risk-benefit ratio is still positive. But we do not have just one vaccine, we have several. So restricting the AstraZeneca vaccine to older people makes sense to me, and it does not waste any doses.”
Denmark and Norway are waiting for more data. Norway, which has administered the AstraZeneca vaccine to 130,000 people under 65, has reported five patients who had low platelets, hemorrhage, and widespread thromboses, three of whom died. That’s about one case in 25,000 vaccinees, "a high number with a very critical outcome in previously healthy, young individuals,” says Watle. The country hopes to make a decision on the vaccine within 3 weeks. It can afford to hold off: COVID-19 cases are relatively low and AstraZeneca is delivering so few doses that the extended pause won’t make a big difference in the short-term.
Middeldorp says she expects more clarity after Monday’s meeting of EMA’s expert group, which includes clotting experts, neurologists, virologists, immunologists and epidemiologists. The agency says it will issue an update on the vaccine during the next meeting of its safety committee, being held from 6 to 9 April. Ideally that meeting will help clarify how frequently the condition occurs and whether the risk varies by age or sex, Middeldorp says. The world needs AstraZeneca’s vaccine, she says—but that means it is crucial to fully understand its benefits and its risks.
Thanks Ev - I think I might have misunderstood the leaseholder bit.